RECRUITING Not applicable ClinicalTrials.gov

Blood Samples Were Taken From Patients Undergoing Oncological Treatment in Order to Validate the TST79 Molecular Test

Sponsor: Grand Hôpital de Charleroi • ClinicalTrials.gov ID: NCT07868640

Registry updated: 2026-10-09

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

The pathological anatomy laboratory, which is managed by the IPG, would involve monitoring patients being treated for cancer and receiving care at the GHDC in order to take blood samples from those in whom the presence of plasma ctDNA carrying a mutation in a specific gene is suspected - a mutation detectable by the TST79 test.

Interventions

Gene-alteration pair (G-A) (Genetic)
Point mutations, small insertions or deletions (indels), gene fusions, copy number amplifications.

Eligibility criteria

Inclusion Criteria: * Patients with the following types of cancer may be invited to donate blood as part of one of two approaches: * lung adenocarcinoma * colorectal adenocarcinoma * breast carcinoma * prostate adenocarcinoma * clear cell renal cell carcinoma * GIST/gastrointestinal stromal tumour * melanoma * urothelial carcinoma * endometrial carcinoma * high-grade ovarian carcinoma

Conditions

Cancer

Locations

Grand Hôpital de Charleroi — Charleroi, Hainaut, Belgium

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment